Food & Drug Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Food & Drug Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Medtronic, Inc.
FDA approves left-heart lead for cardiac resynchronization therapy systems
September 24th, 2004
Medtronic, Inc., (MDT) announced U.S. Food and Drug Administration approval of the Attain 4194 Bipolar over-the-wire left-heart lead for use with cardiac resynchronization systems. This new steroid-eluting lead has an angled shape and can be inserted using either a guidewire or a stylet delivery method, giving physicians an extra option to successfully maneuver and position the lead in a variety of difficult venous anatomies. The Attain 4194 lead is the fourth generation of left-heart leads designed for use with the Medtronic InSync family of cardiac resynchronization therapy (CRT) pacemaker and defibrillator systems. Leads are thin, insulated wires...
Source: Food & Drug Law Weekly (2004-09-24)
|
